| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
JNJ-42041935 is a novel, potent, competitive, reversible, and selective inhibitor of prolyl hydroxylase PHD with pKi values of 7.91±0.04, 7.29 ±0.05, and 7.65±0.09 for PHD1, PHD2, and PHD3, respectively. The hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) enzymes represent novel targets for the treatment of anemia, ulcerative colitis, and ischemic and metabolic disease inter alia. JNJ-42041935 is a new pharmacological tool, which can be used to investigate PHD inhibition and demonstrate that PHD inhibitors offer great promise for the treatment of inflammation-induced anemia.
| ln Vitro |
The most potent PHD2181–417-fold was JNJ-42041935, which had a pIC50 value of 7.0±0.03. The full-length PHD1, PHD2, and PHD3 enzymes (pKi values of 7.91±0.04, 7.29 ±0.05, and 7.65±0.09, respectively) are also inhibited by JNJ-42041935 [1].
|
|---|---|
| ln Vivo |
In a pathway-induced cooling model, JNJ-42041935 was utilized to assess the effects of intermittent high-dose (50 μg/kg ip) exogenous erythropoietin hemostatic agent with the circulating inhibitor PHD. The anemia that was produced was successfully corrected by JNJ-42041935 (100 μMol/kg, once day for 14 days), but erythropoietin promotion had no impact. JNJ-42041935 (100 μMol/kg face) was administered for five days in a row. The rise in reticulocytes was twofold, hemoglobin was increased by 2.3 g/dl, and hematocrit increased by 9%. After administering 300 μMol/kg JNJ-42041935 topically, mice's peritoneal bioluminescence increased by 2.2 ± 0.3 times compared to vehicle controls treated with luciferase [1].
|
| References |
| Molecular Formula |
C12H6N4O3F3CL
|
|---|---|
| Molecular Weight |
346.649
|
| Exact Mass |
346.008
|
| Elemental Analysis |
C, 41.58; H, 1.74; Cl, 10.23; F, 16.44; N, 16.16; O, 13.85
|
| CAS # |
1193383-09-3
|
| PubChem CID |
45102710
|
| Appearance |
White to off-white solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
555.9±60.0 °C at 760 mmHg
|
| Flash Point |
290.0±32.9 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.674
|
| LogP |
3.72
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
23
|
| Complexity |
469
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC(C(C=N1)=CN1C2=NC3=CC(Cl)=C(OC(F)(F)F)C=C3N2)=O
|
| InChi Key |
FXHHASJVTYRJHH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H6ClF3N4O3/c13-6-1-7-8(2-9(6)23-12(14,15)16)19-11(18-7)20-4-5(3-17-20)10(21)22/h1-4H,(H,18,19)(H,21,22)
|
| Chemical Name |
1-(5-chloro-6-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid
|
| Synonyms |
JNJ-42041935; JNJ 42041935; JNJ42041935.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 36 mg/mL (~103.85 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8848 mL | 14.4238 mL | 28.8475 mL | |
| 5 mM | 0.5770 mL | 2.8848 mL | 5.7695 mL | |
| 10 mM | 0.2885 mL | 1.4424 mL | 2.8848 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA